Week In Review: Fosun, WuXi PharmaTech Acquire San Diego's Ambrx
May 23, 2015 at 15:31 PM EDT
Ambrx, a clinical-stage San Diego antibody-conjugate biotech company, will be acquired by a consortium of China companies, including Fosun Pharma and WuXi PharmaTech, plus China equity investors HOPU and Everbright.
